Preview

Ophthalmology in Russia

Advanced search

Features of Diseases of the Anterior Part of the Eye in Patients after COVID-19

https://doi.org/10.18008/1816-5095-2021-2-253-259

Abstract

There are quite systematic data of the ophthalmic manifestations in SARS-CoV-2, on the presence of conjunctivitis in patients with COVID-19, as well as on the detection of viruses in the lacrimal fluid and eye tissues. And, although ophthalmic manifestations are considered rather rare for COVID-19 and are not included in the list of important for diagnosis, there is not enough reliable data on the inflammatory processes of the eye’s anterior part and their connection with COVID-19, as well as those arising against the background of the treatment.

Purpose. To study the development of inflammatory diseases of the anterior part of the eye in patients who have undergone the new coronavirus infection COVID-19.

resu. In the Department of Infectious and Allergic Eye Diseases of the Helmholts National Medical Research Center of Eye Diseases, 88 patients with confirmed transferred new coronavirus infection COVID-19 of varying severity were observed. The main method of laboratory diagnostics is the detection of SARS-CoV-2 RNA in swabs from the nasopharynx, the patient’s sputum. Serodiagnostics of COVID-19 includes the determination of IgG-, IgM-antibodies to SARS-CoV-2 in the blood in an enzyme-linked immunosorbent assay.

Results. Acute conjunctivitis associated with COVID-19 is quite rare and is an early sign of the disease. In the complex nonspecific topical therapy of viral conjunctivitis in COVID-19, along with etiopathogenetic systemic treatment, local eye medications with immunomodulatory and antiviral activity should be used. Conjunctivitis during a pandemic may be the only sign of COVID-19. The development of allergic conjunctivitis in COVID-19 is possibly associated not only with the effect of a viral agent, but also depends on the toxic effect of drugs used in the complex treatment of this disease. The increase in the number of patients with episcleritis after the postponed coronavirus infection needs further detailed study, with the analysis of laboratory data from this group of patients and the accumulation of clinical material.

Conclusion. Ophthalmic manifestations in COVID-19 are very different, affecting various structures of the eye, occur at different periods — both during the course of the disease and after clinical recovery, and, of course, need further consideration, study and structuring. 

About the Authors

E. V. Yani
Helmholts National Medical Research Center of Eye Diseases
Russian Federation

PhD, head of the Infectious and Allergic Eye Diseases Department,

Sadovaya Chernogryazskaya str., 14/19, Moscow, 105062



E. N. Orlova
Helmholts National Medical Research Center of Eye Diseases
Russian Federation

PhD, scientific secretary,

Sadovaya Chernogryazskaya str., 14/19, Moscow, 105062



K. E. Seliverstova
Helmholts National Medical Research Center of Eye Diseases
Russian Federation

head of the Infectious and Allergic Eye Diseases Department, ophthalmologist,

Sadovaya Chernogryazskaya str., 14/19, Moscow, 105062



References

1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., Wang W., Song H., Huang B., Zhu N., Bi Y., Ma X., Zhan F., Wang L., Hu T., Zhou H., Hu Z., Zhou W., Zhao L., Chen J., Meng Y., Wang J., Lin Y., Yuan J., Xie Z., Ma J., Liu WJ., Wang D., Xu W., Holmes EC., Gao GF., Wu G., Chen W., Shi W., Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020 Feb 22;395(10224):565–574. DOI: 10.1016/S01406736(20)30251-8

2. To K.F., Lo A.W. Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV) and its putative receptor, angiotensin-converting enzyme 2 (ACE2). The Journal of pathology. 2004 Jul;203(3):740–743. DOI: 10.1002/path.1597

3. Guo Y.R., Cao Q.D., Hong Z.S., Tan Y.Y., Chen S.D., Jin H.J., Tan K.S., Wang D.Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak — an update on the status. Military Medical Research 2020;7(1):1. DOI: 10.1186/s40779-020-00240-0

4. Tu H., Tu S., Gao S., Shao A., Sheng J. Current epidemiological and clinical features of COVID-19; a global perspective from China. The Journal of infection. 2020;81(1):1–9. DOI: 10.1016/j.jinf.2020.04.011

5. Peiris J.S., Yuen K.E., Osterhaus A., Stöhr K. The severe acute respiratory syndrome. The New England journal of medicine. 2003 Dec 18;349(25):2431–2441. DOI: 10.1056/NEJMra032498

6. Xia J., Tong J., Liu M., Shen Y., Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. Journal of medical virology. 2020 Jun;92(6):589–594. DOI: 10.1002/jmv.25725

7. Rothe C., Schunk M., Sothmann P., Bretzel G., Froeschl G., Wallrauch C., Zimmer T., Thiel V., Janke C., Guggemos W., Seilmaier M., Drosten C., Vollmar P., Zwirglmaier K., Zange S., Wölfel R., Hoelscher M. Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany. The New England journal of medicine. 2020;382(10):970–971. DOI: 10.1056/NEJMc2001468.30

8. Zou L., Ruan F., Huang M., Liang L., Huang H., Hong Z., Yu J., Kang M., Song Y., Xia J., Guo Q., Song T., He J., Yen H.L., Peiris M., Wu J. SARS-Cov-2 Viral Load in Upper Respiratory Specimens of Infected Patients. The New England journal of medicine. 2020 :382(12):1177–1179. DOI: 10.1056/NEJMc2001737

9. Smirnov V.S., Totolyan A.A. Innate immunity in coronavirus infection. Russian Journal of Infection and Immunity = Infekciya i immunitet 2020;10(2):259–268 (In Russ.). DOI: 10.15789/2220-7619-III-1440

10. Wölfel R., Corman V.M., Guggemos W., Seilmaier M., Zange S., Müller M.A., Niemeyer D., Jones T.C., Vollmar P., Rothe C., Hoelscher M., Bleicker T., Brünink S., Schneider J., Ehmann R., Zwirglmaier K., Drosten C., Wendtner C. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465– 469. DOI: 10.1038/s41586-020-2196-x

11. Javorac D., Grahovac L., Manić L., Stojilković N., Anđelković M., Bulat Z., ĐukićĆosić D., Curcic M., Djordjevic A.B. An overview of the safety assessment of medicines currently used in the COVID-19 disease treatment. Food and chemical toxicology: an international journal published for the British Industrial Biological Research Association. 2020 Oct;144:111639. DOI: 10.1016/j.fct.2020.111639

12. Lu C.W., Liu X.F., Jia Z.F. 2019-nCoV transmission through the ocular surface must not be ignored. Lancet. 2020;395:e39. DOI: 10.1016/S0140-6736(20)30313-5

13. Li J.O., Lam D.S.C., Chen Y., Ting D.S. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. The British journal of ophthalmology. 2020;104:297– 298. DOI: 10.1136/bjophthalmol-2020-315994.

14. BenEzra D. Blepharitis and Conjunctivitis. Guidelines for diagnosis and treatment. Editonal. glosa 2006 248 p.

15. Neroev V.V., Vakhova E.S. Diseases of the conjunctiva. In: Ophthalmology. National leadership. Ed. by Avetisov S.E., Egorov E.A., Moshetova L.K., Neroeva V.V., Takhchidi H.P. Moscow: GEOTAR-Media, 2018. 418 p (In Russ.)


Review

For citations:


Yani E.V., Orlova E.N., Seliverstova K.E. Features of Diseases of the Anterior Part of the Eye in Patients after COVID-19. Ophthalmology in Russia. 2021;18(2):253-259. (In Russ.) https://doi.org/10.18008/1816-5095-2021-2-253-259

Views: 1151


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1816-5095 (Print)
ISSN 2500-0845 (Online)